Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
INmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript
02:51am, Friday, 03'rd Mar 2023
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scie
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
09:00am, Tuesday, 21'st Feb 2023
Management to host conference call and webcast at 4:30 pm ET on that day
INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts
07:45am, Thursday, 05'th Jan 2023
INmune Bio has multiple potential catalysts ahead including the go-ahead to start Phase 2 trials with XPro in the US. The company will soon file an IND for its immunotherapy candidate INKmune in a sol
INmune Bio, High Risk, Higher Reward.
12:45pm, Monday, 21'st Nov 2022
The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities. XPro looks especially promising in mild cognitiv
INmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript
06:35pm, Thursday, 03'rd Nov 2022
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnu
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
08:10am, Wednesday, 26'th Oct 2022
Management to host conference call and webcast at 4:30 pm E T on that day
INmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call Transcript
09:55pm, Wednesday, 03'rd Aug 2022
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Co-Founder and Chief E
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
09:47am, Tuesday, 07'th Jun 2022
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
01:48pm, Wednesday, 25'th May 2022
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
INmune Bio: Possibly The Once In A Lifetime Dip
11:28am, Wednesday, 25'th May 2022
INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB's share price just dropped at an all-time low due to a US-related clinical hold for X
INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade
08:59am, Tuesday, 24'th May 2022
Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Dr
INmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call Transcript
01:39am, Sunday, 08'th May 2022
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Execut
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
07:00am, Thursday, 28'th Apr 2022
Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
05:19pm, Thursday, 14'th Apr 2022
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
08:00am, Monday, 11'th Apr 2022
Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, a
